Clinical Effects and Safety of the Use of Methylene Blue for the Treatment of Lumbar Facet Joint Syndrome.

研究概要

One hundred and twenty patients with lumbar facet joint syndrome due to osteoarthritis were randomized to receive an ultrasound-guided intra-articular injection of methylene blue (n=60) or diprospan (n=60). The primary outcome of interest was pain on a Numeric Rating Scale (NRS), measured up to 6 months post-operation. Secondary outcomes of interest included lumbar function, sleep quality, depression severity, treatment efficacy, post-operative analgesic consumption, and the incidence of complications. Results revealed significantly lower pain scores, better lumbar function and sleep quality, lower depression severity, and a lower incidence of hyperglycemia with methylene blue injection vs. control.